$BLUE
bluebird bio, Inc.

2022 Q4 Form 10-Q Financial Statement

#000129397122000063 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $63.00K $71.00K
YoY Change -96.08% -93.03%
Cost Of Revenue $21.00K $0.00
YoY Change -99.95% -100.0%
Gross Profit $42.00K $71.00K
YoY Change -100.12% -100.38%
Gross Profit Margin 66.67% 100.0%
Selling, General & Admin $30.71M $33.40M
YoY Change -85.38% -51.08%
% of Gross Profit 73111.9% 47045.07%
Research & Development $45.90M $53.15M
YoY Change -85.65% -59.56%
% of Gross Profit 109285.71% 74857.75%
Depreciation & Amortization $1.256M $1.387M
YoY Change -45.72% -76.81%
% of Gross Profit 2990.48% 1953.52%
Operating Expenses $76.61M $86.55M
YoY Change -85.54% -56.66%
Operating Profit -$76.57M -$84.78M
YoY Change -43.56% -45.11%
Interest Expense $369.0K $383.0K
YoY Change -98.78% 20.06%
% of Operating Profit
Other Income/Expense, Net $6.538M $7.885M
YoY Change -474.03% -2781.97%
Pretax Income $32.34M -$76.51M
YoY Change -105.75% -64.73%
Income Tax $110.0K $7.000K
% Of Pretax Income 0.34%
Net Earnings $32.23M -$76.52M
YoY Change -120.79% -64.71%
Net Earnings / Revenue 51161.9% -107774.65%
Basic Earnings Per Share -$0.94
Diluted Earnings Per Share $0.38 -$0.94
COMMON SHARES
Basic Shares Outstanding 82.91M shares 77.12M shares
Diluted Shares Outstanding 81.54M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.7M $141.0M
YoY Change -54.18% -85.47%
Cash & Equivalents $113.0M $66.48M
Short-Term Investments $68.74M $74.56M
Other Short-Term Assets $19.16M $20.81M
YoY Change -48.24% -49.62%
Inventory $0.00
Prepaid Expenses $8.374M $8.270M
Receivables
Other Receivables
Total Short-Term Assets $199.5M $160.4M
YoY Change -40.72% -80.72%
LONG-TERM ASSETS
Property, Plant & Equipment $9.362M $11.54M
YoY Change -3.54% -74.78%
Goodwill $5.646M $5.646M
YoY Change 0.0% -53.17%
Intangibles $4.868M
YoY Change
Long-Term Investments $1.414M $1.407M
YoY Change -98.54% -99.27%
Other Assets $52.13M $52.39M
YoY Change -2.16% -26.16%
Total Long-Term Assets $355.4M $359.7M
YoY Change 38.15% -29.11%
TOTAL ASSETS
Total Short-Term Assets $199.5M $160.4M
Total Long-Term Assets $355.4M $359.7M
Total Assets $554.9M $520.1M
YoY Change -6.55% -61.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.09M $18.62M
YoY Change -3.06% -14.06%
Accrued Expenses $100.9M $105.0M
YoY Change -18.42% -46.82%
Deferred Revenue $1.502M $1.565M
YoY Change -34.18% -38.14%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $128.2M $126.7M
YoY Change -16.18% -52.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $92.00K $92.00K
YoY Change -1.08% -98.84%
Total Long-Term Liabilities $92.00K $92.00K
YoY Change -1.08% -98.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $128.2M $126.7M
Total Long-Term Liabilities $92.00K $92.00K
Total Liabilities $358.6M $361.2M
YoY Change 63.34% -23.0%
SHAREHOLDERS EQUITY
Retained Earnings -$3.990B -$4.020B
YoY Change 7.26% 12.92%
Common Stock $830.0K $829.0K
YoY Change 16.74% 18.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $196.3M $158.9M
YoY Change
Total Liabilities & Shareholders Equity $554.9M $520.1M
YoY Change -6.55% -61.18%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $32.23M -$76.52M
YoY Change -120.79% -64.71%
Depreciation, Depletion And Amortization $1.256M $1.387M
YoY Change -45.72% -76.81%
Cash From Operating Activities -$56.27M -$77.03M
YoY Change -59.73% -47.58%
INVESTING ACTIVITIES
Capital Expenditures $5.108M -$1.264M
YoY Change -348.08% -87.02%
Acquisitions
YoY Change
Other Investing Activities $108.4M $16.87M
YoY Change 72.01% -86.99%
Cash From Investing Activities $103.2M $15.61M
YoY Change 69.44% -86.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -115.0K 46.33M
YoY Change -99.93% -38.94%
NET CHANGE
Cash From Operating Activities -56.27M -77.03M
Cash From Investing Activities 103.2M 15.61M
Cash From Financing Activities -115.0K 46.33M
Net Change In Cash 46.85M -15.09M
YoY Change -118.53% -130.9%
FREE CASH FLOW
Cash From Operating Activities -$56.27M -$77.03M
Capital Expenditures $5.108M -$1.264M
Free Cash Flow -$61.38M -$75.76M
YoY Change -55.41% -44.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Local Phone Number
LocalPhoneNumber
499-9300
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001293971
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 blue Common Stock Convertible Conversion Ratio
CommonStockConvertibleConversionRatio
0.3333
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35966
dei Entity Registrant Name
EntityRegistrantName
bluebird bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3680878
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Grand Union Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
Somerville
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02145
dei City Area Code
CityAreaCode
339
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
BLUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82909980 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66478000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161160000 usd
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
73155000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
138343000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8270000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
25628000 usd
CY2022Q3 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
12535000 usd
CY2021Q4 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
11389000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
160438000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
336520000 usd
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1407000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
97114000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11535000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9706000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
5646000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
5646000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288684000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91532000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52388000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53277000 usd
CY2022Q3 us-gaap Assets
Assets
520098000 usd
CY2021Q4 us-gaap Assets
Assets
593795000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18622000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
25883000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
64314000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
103958000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
43791000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23152000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
126727000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
152993000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
234422000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66432000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
92000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
93000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
361241000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
219518000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82880000 shares
CY2021Q3 us-gaap Revenues
Revenues
1019000 usd
us-gaap Revenues
Revenues
3534000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82880000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71115000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71115000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
829000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
711000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4181393000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4096402000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4630000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2911000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4018735000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3719925000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
158857000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
374277000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
520098000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
593795000 usd
CY2022Q3 us-gaap Revenues
Revenues
71000 usd
us-gaap Revenues
Revenues
2056000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53149000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
155468000 usd
us-gaap Costs And Expenses
CostsAndExpenses
316061000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73679000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
194864000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
240561000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33402000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42229000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
106201000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
156763000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19385000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10056000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35176000 usd
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
-1699000 usd
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
20175000 usd
us-gaap Restructuring Charges
RestructuringCharges
4940000 usd
us-gaap Restructuring Charges
RestructuringCharges
24800000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
84852000 usd
us-gaap Costs And Expenses
CostsAndExpenses
457300000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-84781000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-154449000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-312527000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-455244000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
383000 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
160000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
663000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
733000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7885000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1342000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13061000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24369000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76513000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-152947000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-298803000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-430142000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-76520000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-152834000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-298810000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-113000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
169000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-430311000 usd
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-63982000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-234015000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-76520000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-216816000 usd
us-gaap Net Income Loss
NetIncomeLoss
-298810000 usd
us-gaap Net Income Loss
NetIncomeLoss
-664326000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.94
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.94
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.23
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.23
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.91
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.91
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.36
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.36
CY2022Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2022Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2021Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-0.93
CY2021Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.93
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-3.46
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-3.46
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.16
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.81
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81543000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81543000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68621000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68621000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76361000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76361000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67701000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67701000 shares
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-216945000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-214000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-129000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1719000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-401000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-214000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-129000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1719000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-401000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76734000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-300529000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-664727000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
374277000 usd
CY2022Q1 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12681000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1548000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-122152000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
263259000 usd
CY2022Q2 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8043000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8908000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
43000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-100138000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
180116000 usd
CY2022Q3 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
239000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46024000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9212000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-214000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-76520000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
158857000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1355056000 usd
CY2021Q1 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1219000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1707000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36090000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12013000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
56000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-205808000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1200333000 usd
CY2021Q2 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26222000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-328000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-241702000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
984561000 usd
CY2021Q3 blue Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
233000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37499000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2475000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
37477000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
875000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24352000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-129000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-216816000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
870527000 usd
us-gaap Net Income Loss
NetIncomeLoss
-298810000 usd
us-gaap Net Income Loss
NetIncomeLoss
-664326000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
28765000 usd
blue Inventory Excess Valuation Reserves
InventoryExcessValuationReserves
7519000 usd
blue Inventory Excess Valuation Reserves
InventoryExcessValuationReserves
29712000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
464000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3745000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
17335000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
30509000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
101829000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-3135000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2890000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13358000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6197000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15720000 usd
blue Lessee Increase Decrease In Operating Lease Right Of Use Asset
LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset
29650000 usd
blue Lessee Increase Decrease In Operating Lease Right Of Use Asset
LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset
22630000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7552000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
802367000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
30216000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2004000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-39046000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
54774000 usd
blue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-22523000 usd
blue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-24499000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
210000 usd
blue Increase Decrease In Collaborative Research Advancement
IncreaseDecreaseInCollaborativeResearchAdvancement
0 usd
blue Increase Decrease In Collaborative Research Advancement
IncreaseDecreaseInCollaborativeResearchAdvancement
4920000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-296680000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-495914000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8100000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12944000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
421416000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
125095000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
459499000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
31318000 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
110300000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
147211000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
501625000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5078000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54368000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80060000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-95101000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
85771000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
206693000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
373728000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111592000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66478000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402461000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1565000 usd
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
2530000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
43549000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54508000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111592000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
459499000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
176000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
732000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
298000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
229636000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22049000 usd
blue Reduction Of Right Of Use Asset And Associated Lease Liability Due To Reassessment
ReductionOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment
-2833000 usd
blue Reduction Of Right Of Use Asset And Associated Lease Liability Due To Reassessment
ReductionOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment
-9004000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
14488000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of the business<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial-readiness activities, and to its commercialization efforts relating to its approved products. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s programs in severe genetic diseases include ZYNTEGLO® (betibeglogene autotemcel, or "beti-cel", formerly "LentiGlobin for β-thalassemia gene therapy"), which was approved by the U.S. Food and Drug Administration ("FDA") in August 2022 for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions; SKYSONA® (elivaldogene autotemcel, or "eli-cel", formerly "Lenti-D gene therapy") which was granted Accelerated Approval by the FDA in September 2022 to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy ("CALD"); and lovotibeglogene autotemcel ("lovo-cel", formerly "LentiGlobin for SCD") being developed as a treatment for sickle cell disease ("SCD"). </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company announced its intent to focus its severe genetic disease business on the U.S. market and further invest in research and development for its core programs in β-thalassemia, SCD, and CALD. As part of the strategy to focus on the U.S. market, it began executing an orderly wind down of its European operations, which resulted in a reduction of selling, general and administrative costs and had an impact on the Company's excess inventory analysis, which is based on sales forecasts and projected inventory consumption levels.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed the separation of its severe genetic disease and oncology programs into two separate, independent publicly traded companies, bluebird bio, Inc. and 2seventy bio, Inc. (“2seventy bio”), a Delaware corporation and wholly-owned subsidiary of the Company prior to the separation. bluebird retained its severe genetic disease programs, including programs for β-thalassemia, SCD, and CALD, with a focus on the U.S. market.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Board of Directors approved a comprehensive restructuring plan intended to reduce operating expenses and enhance the Company’s focus on achieving FDA approval for its programs in the U.S. The Company intends to maintain targeted research efforts focused on in-vivo lentiviral vector ("LVV") gene therapy and to deprioritize direct investments in reduced toxicity conditioning and cryopreserved apheresis. As part of the restructuring, bluebird reduced its workforce by approximately 30% across the second and third quarters of 2022. Refer to Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reduction in workforce, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on this restructuring.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Goldman Sachs &amp; Co. LLC (“Goldman”) to sell shares of the Company’s common stock up to $75.0 million, from time to time, through an “at the market” equity offering program under which Goldman will act as manager. The Equity Distribution Agreement also provides for the sale of shares to Goldman directly as principal, in which case the Company and Goldman will enter into a separate terms agreement. The Company will pay Goldman a commission equal to up to 3.0% of the gross proceeds of any Common Stock sold through Goldman under the Equity Distribution Agreement. As of September 30, 2022, the Company sold 10.7 million shares of common stock at-the-market under the Equity Distribution Agreement, resulting in gross proceeds to the Company of approximately $56.2 million ($54.1 million net of offering costs). Refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q for more information.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $141.0 million. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from charitable foundations. As of September 30, 2022, the Company had an accumulated deficit of $4.02 billion. During the nine months ended September 30, 2022, the Company incurred a loss of $298.8 million and used $296.7 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development, approval, and commercialization of lovo-cel, the successful commercialization of ZYNTEGLO and SKYSONA and the achievement of a level of revenues adequate to support its cost structure. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 205-40"), the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, the release of restricted cash related to the Company’s 50 Binney Street lease, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have been approved by the Board of Directors as of the date of these condensed consolidated financial statements. The restructuring plan described above was approved by the Board of Directors in April 2022 and therefore was incorporated into the Company's assessment of its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include implementing reduced 2022 spending, including projected savings through the move of the Company's headquarters to Assembly Row in Somerville, Massachusetts, the completion of its orderly wind down of European operations, the completion of its April 2022 restructuring plans, the potential sale of priority review vouchers issued with the U.S. regulatory approvals of ZYNTEGLO and SKYSONA, and the pursuit of additional cash resources through public or private equity or debt financings. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. In accordance with ASC 205-40, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these condensed consolidated financial statements. </span></div>The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
CY2022Q3 us-gaap Investments And Cash
InvestmentsAndCash
141000000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4020000000.00 usd
us-gaap Net Income Loss
NetIncomeLoss
-298800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-296700000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.</span></div>
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 blue Number Of Transition Services Agreements
NumberOfTransitionServicesAgreements
2 agreement
CY2021Q4 blue Transition Services Agreement Initial Term
TransitionServicesAgreementInitialTerm
P2Y
CY2022Q3 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
0 usd
CY2022Q3 blue Equity Securities Unrealized Gain
EquitySecuritiesUnrealizedGain
0 usd
CY2022Q3 blue Equity Securities Unrealized Loss
EquitySecuritiesUnrealizedLoss
0 usd
CY2022Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
0 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
235456000 usd
CY2022Q3 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
76852000 usd
CY2022Q3 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
0 usd
CY2022Q3 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
2290000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
74562000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
4305000 usd
CY2021Q4 blue Equity Securities Unrealized Gain
EquitySecuritiesUnrealizedGain
0 usd
CY2021Q4 blue Equity Securities Unrealized Loss
EquitySecuritiesUnrealizedLoss
614000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
3691000 usd
CY2021Q4 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
236638000 usd
CY2021Q4 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
0 usd
CY2021Q4 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
1182000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q2 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
600000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Interest Receivable
InterestReceivable
100000 usd
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
300000 usd
blue Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
CY2021Q3 blue Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
CY2022Q3 blue Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
blue Interest Receivable Write Off
InterestReceivableWriteOff
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
34785000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1054000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
39777000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1236000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
74562000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2290000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
153737000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1523000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1665000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
561000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
6392000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
6000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
160129000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
567000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29700000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-400000 usd
CY2022Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
0 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
3700000 usd
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31300000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35107000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30112000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23572000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20406000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11535000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9706000 usd
CY2022Q3 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
17226000 usd
CY2021Q4 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
15722000 usd
CY2022Q3 blue Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
9692000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1565000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2282000 usd
CY2021Q4 blue Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
24273000 usd
CY2022Q3 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
13609000 usd
CY2021Q4 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
17769000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19163000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41095000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1536000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1152000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
64314000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
103958000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
15000000 usd
CY2022Q3 blue Purchase Obligation Cumulative Increase Decrease
PurchaseObligationCumulativeIncreaseDecrease
-26700000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2800000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2700000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5300000 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9200000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21300000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30500000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75700000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9212000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21254000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30509000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75674000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9212000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21254000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30509000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75674000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3586000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1034000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1893000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
40.74
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2725000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.78
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1231000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
45.69
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2725000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.78
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7088000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10158000 shares

Files In Submission

Name View Source Status
0001293971-22-000063-index-headers.html Edgar Link pending
0001293971-22-000063-index.html Edgar Link pending
0001293971-22-000063.txt Edgar Link pending
0001293971-22-000063-xbrl.zip Edgar Link pending
blue-20220930.htm Edgar Link pending
blue-20220930.xsd Edgar Link pending
blue-20220930xex101.htm Edgar Link pending
blue-20220930xex103.htm Edgar Link pending
blue-20220930xex104.htm Edgar Link pending
blue-20220930xex105.htm Edgar Link pending
blue-20220930xex106.htm Edgar Link pending
blue-20220930xex311.htm Edgar Link pending
blue-20220930xex312.htm Edgar Link pending
blue-20220930xex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
blue-20220930_def.xml Edgar Link unprocessable
blue-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blue-20220930_lab.xml Edgar Link unprocessable
blue-20220930_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blue-20220930_cal.xml Edgar Link unprocessable